NCT01803178

Brief Summary

The main aim of the study is to investigate, in humans, the effect of plant sterols on vascular function by measuring flow-mediated dilation (FMD). This study also aims to study the effect of plant sterols on pulse wave velocity (PWV), aortic augmentation index (Aix), central blood pressure (CBP), office blood pressure (BP), blood lipids and plasma plant sterol concentration. At last, the effects of plant sterols on z-scores of circulating biomarkers of endothelial dysfunction and low-grade inflammation will be assessed. For all study outcomes, effect sizes and 95% confidence intervals will be estimated. Hypothesis: Based on available evidence, it is hypothesized that plant sterols modestly increase FMD.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
240

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Feb 2013

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2013

Completed
25 days until next milestone

First Submitted

Initial submission to the registry

February 26, 2013

Completed
6 days until next milestone

First Posted

Study publicly available on registry

March 4, 2013

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2013

Completed
Last Updated

October 28, 2013

Status Verified

February 1, 2013

Enrollment Period

6 months

First QC Date

February 26, 2013

Last Update Submit

October 25, 2013

Conditions

Keywords

vascular functionplant sterolsblood lipids

Outcome Measures

Primary Outcomes (1)

  • Change in flow-mediated dilation

    At baseline (after 4 weeks run-in period) and after 12 weeks intervention

Secondary Outcomes (1)

  • Change in pulse wave velocity

    At baseline (after 4 weeks run-in period) and after 12 weeks intervention

Other Outcomes (6)

  • Change in blood lipids

    At baseline (after 4 weeks run-in period) and after 4, 8 and 12 weeks intervention

  • Change in plasma plant sterols

    At baseline (after 4 weeks run-in period) and after 4, 8 and 12 weeks intervention

  • Change in plasma biomarkers of endothelial dysfunction and low-grade inflammation

    At baseline (after 4 weeks run-in period) and after 12 weeks intervention

  • +3 more other outcomes

Study Arms (2)

Plant Sterols

ACTIVE COMPARATOR

Plant Sterols

Dietary Supplement: Plant Sterols

Placebo Product

PLACEBO COMPARATOR

Placebo Product

Dietary Supplement: Placebo Product

Interventions

Plant SterolsDIETARY_SUPPLEMENT
Plant Sterols
Placebo ProductDIETARY_SUPPLEMENT
Placebo Product

Eligibility Criteria

Age40 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Apparently healthy men and post-menopausal women
  • BMI ≥ 18 and ≤ 30 kg/m2.
  • Aged between 40 - 65 years.
  • Having elevated LDL-cholesterol concentrations at screening (130-190 mg/dL or 3.4-4.9 mmol/L).
  • Blood pressure, heart rate, haematological and clinical chemical parameters within the normal reference range as judged by the research physician

You may not qualify if:

  • Having (previous) cardiovascular event(s) (stroke, TIA, angina, myocardial infarction, heart failure), systemic inflammatory conditions or diabetes mellitus.
  • Use of over-the-counter and prescribed medication which may interfere with study measurements (i.e. statins, ezetimibe, fibrates, diabetic drugs, ARB and ACE inhibitors), to be judged by the Principal Investigator.
  • Use of medical treatment for elevated TG concentrations.
  • Use of antibiotics in the three months prior to screening.
  • Currently smoking or being a non-smoker for less than 6 months and reported use of any nicotine containing products in the 6 months prior to screening and/or during the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Charité Research Organisation

Berlin, Germany

Location

Related Publications (3)

  • Ras RT, Fuchs D, Koppenol WP, Schalkwijk CG, Otten-Hofman A, Garczarek U, Greyling A, Wagner F, Trautwein EA. Effect of a plant sterol-enriched spread on biomarkers of endothelial dysfunction and low-grade inflammation in hypercholesterolaemic subjects. J Nutr Sci. 2016 Dec 6;5:e44. doi: 10.1017/jns.2016.40. eCollection 2016.

  • Ras RT, Koppenol WP, Garczarek U, Otten-Hofman A, Fuchs D, Wagner F, Trautwein EA. Increases in plasma plant sterols stabilize within four weeks of plant sterol intake and are independent of cholesterol metabolism. Nutr Metab Cardiovasc Dis. 2016 Apr;26(4):302-9. doi: 10.1016/j.numecd.2015.11.007. Epub 2015 Dec 12.

  • Ras RT, Fuchs D, Koppenol WP, Garczarek U, Greyling A, Keicher C, Verhoeven C, Bouzamondo H, Wagner F, Trautwein EA. The effect of a low-fat spread with added plant sterols on vascular function markers: results of the Investigating Vascular Function Effects of Plant Sterols (INVEST) study. Am J Clin Nutr. 2015 Apr;101(4):733-41. doi: 10.3945/ajcn.114.102053.

MeSH Terms

Conditions

Vascular DiseasesHypercholesterolemia

Interventions

Phytosterols

Condition Hierarchy (Ancestors)

Cardiovascular DiseasesHyperlipidemiasDyslipidemiasLipid Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

SterolsCholestanesSteroidsFused-Ring CompoundsPolycyclic CompoundsMembrane LipidsLipidsPhytochemicalsBiological Factors

Study Officials

  • Wieneke Koppenol, MSc

    Unilever Research & Development

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 26, 2013

First Posted

March 4, 2013

Study Start

February 1, 2013

Primary Completion

August 1, 2013

Study Completion

August 1, 2013

Last Updated

October 28, 2013

Record last verified: 2013-02

Locations